These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Kabbara WK; Ramadan WH J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757 [TBL] [Abstract][Full Text] [Related]
32. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients. Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197 [TBL] [Abstract][Full Text] [Related]
33. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia. Rodriguez C; Nere ML; Demontant V; Charreau I; Mercier-Darty M; Delagreverie H; Salmona M; de Castro N; Chaix ML; Molina JM; Delaugerre C J Antimicrob Chemother; 2018 Nov; 73(11):3122-3128. PubMed ID: 30137335 [TBL] [Abstract][Full Text] [Related]
34. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF; Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392 [TBL] [Abstract][Full Text] [Related]
35. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen. Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814 [TBL] [Abstract][Full Text] [Related]
36. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026 [TBL] [Abstract][Full Text] [Related]
38. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy. Rokx C; Verbon A; Rijnders BJ HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660 [TBL] [Abstract][Full Text] [Related]
39. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K; Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935 [TBL] [Abstract][Full Text] [Related]
40. HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy. Michelini Z; Galluzzo CM; Pirillo MF; Francisci D; Degli Antoni A; Vivarelli A; Ladisa N; Cirioni O; Weimer LE; Fragola V; Cara A; Floridia M; Baroncelli S J Med Virol; 2016 Dec; 88(12):2115-2124. PubMed ID: 27197719 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]